We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Matthew
Harding
matt.harding@cpft.nhs.uk
Prof
Dag
Aarsland
dag.aarsland@kcl.ac.uk
Other degenerative diseases of the nervous systemOrganic, including symptomatic, mental disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
There are 800,000 people with dementia in the UK, and this is expected to rise to over 1 million by 2025. Accurate diagnosis is critical in overall management of patients. Important new findings have shown that biomarkers such as cerebrospinal fluid (CSF) and brain imaging can help to accurately diagnose Alzheimer’s disease (AD). Biomarkers have now been included in the most recent diagnosis guidelines for AD. Less is known about biomarkers for dementia with Lewy bodies (DLB) and dementia associated with Parkinson’s disease (PDD), which together account for 15-20% of all dementia cases. Typically, DLB and PDD are characterised in patients by the presence of cognitive impairments, visual hallucinations and motor symptoms. DLB is diagnosed when dementia develops without parkinsonian symptoms (motor symptoms) or within a year of the onset of parkinsonian symptoms. PDD develops in a context of well-defined Parkinson’s Disease (PD) diagnosis as compared to DLB. Patients with DLB symptoms are frequently misdiagnosed due to their symptoms overlapping with AD and PD. Compared to AD, patients with DLB are particularly sensitive to psychiatric drugs, and have a worse outcome. It is therefore important to accurately diagnose these patients. Early findings indicate that measuring specific markers in CSF can also help to predict the worsening of thinking abilities in DLB.
In this study we will collect CSF, blood and neuroimaging data from 207 patients with suspected DLB, AD or PDD. We expect the majority will have mild dementia or very early problems like mild cognitive impairment. Full analysis of biological samples will be performed by researchers at King’s College London. In addition to already known measures of AD, we will examine new markers in order to see whether they can predict accurately disease outcomes for DLB. Patients will be followed up for three years, with biological markers completed at the beginning of the study and cognitive tests and questionnaires done every year.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Exclusion criteria 1. Severe physical or life-threatening conditions which may limit ability for the subject to participate in the study. This includes cancer or other conditions with suspected survival time less than three years. 2. Other intracranial pathology (stroke, space occupying lesion, previous intracranial surgery) 3. Other physical or psychiatric conditions which may contribute to cognitive impairment 4. Diagnosis of possible DLB with negative dopamine transporter scan (DaT scan) 5. More than five years use of antipsychotic drugs prior to diagnosis 6. Contraindications to Lumbar Puncture including warfarin and anticoagulant use (if patient has consented to lumbar puncture). 8. Project Partner who is unable to attend all study visits with the participant.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by King's College London and funded by ALZHEIMER'S RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 40304
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
